Equity Research firms currently have a positive stance on shares of Ascendis Pharma A/S (NASDAQ:ASND). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.00. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $30.67 on a short term basis.
At the time of writing, the stock was trading at $20.00. This represents a change from the opening price of -0.20%. In terms of performance, year to date, the stock is 9.28%. The monthly stock performance comes in at 1.47%. For the quarter, shares are performing at 54.24%. Weekly performance analysis shows the equity at -1.43%.
In taking a look at technical levels, shares are trading 10.72% away from the 50 day simple moving average and 20.08% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -7.83% away from it’s 52- week high and 67.79% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Ascendis Pharma A/S’s RSI stands at 57.85. In looking at volatility levels, the shares saw weekly volatility of 2.13% and 4.76% over the past month.